Synlogic (NASDAQ:SYBX) Share Price Passes Above Fifty Day Moving Average – Should You Sell?

Posted by Amy Steele on Jul 31st, 2026

Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.72 and traded as high as $1.20. Synlogic shares last traded at $1.15, with a volume of 485,293 shares traded.

Synlogic Stock Performance

The stock has a market cap of $13.45 million, a P/E ratio of -4.42 and a beta of 0.54. The business has a 50 day simple moving average of $0.72 and a 200-day simple moving average of $0.68.

Hedge Funds Weigh In On Synlogic

A number of hedge funds and other institutional investors have recently made changes to their positions in SYBX. Renaissance Technologies LLC increased its holdings in Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after buying an additional 46,117 shares during the last quarter. Citadel Advisors LLC bought a new stake in Synlogic in the third quarter worth about $49,000. Finally, DRW Securities LLC bought a new stake in Synlogic in the fourth quarter worth about $27,000. 63.40% of the stock is owned by hedge funds and other institutional investors.

Synlogic Company Profile

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.